A Case of End-stage Post-Covid-19 Pulmonary Fibrosis in a Kenyan Hospital
Downloads
Post-COVID-19 pulmonary fibrosis (PC19-PF) is one of the severe manifestations of the “long COVID syndrome,” with a prevalence of about 7%, and is characterized by the presence of persistent fibrotic lung changes (on a CT scan of the lungs) associated with impairment of pulmonary function. Some of the risk factors for PC19-PF include advanced age, the occurrence of acute respiratory distress syndrome (ARDS), the need for supplemental oxygen, mechanical ventilation, smoking, etc. Antifibrotic agents, e.g., pirfenidone and nintedanib, are increasingly being used in the management of PC19-PF with good outcomes, but larger studies on efficacy and benefit are needed. In this study, we present the case of a young woman in a rural Kenyan hospital found to have end-stage PC19-PF needing long-term oxygen therapy to highlight the reality of PC19-PF in the post-COVID-19 clinical era.
Downloads
Davis, H.E., et al., Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol, 2023. 21(3): p. 133-146.
Chen, C., et al., Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis, 2022. 226(9): p. 1593-1607.
Alrajhi, N.N., Post-COVID-19 pulmonary fibrosis: An ongoing concern. Ann Thorac Med, 2023. 18(4): p. 173-181.
Tanni, S.E., et al., Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med, 2021. 15(6): p. 791-803.
Groff, D., et al., Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open, 2021. 4(10): p. e2128568.
Ojo, A.S., et al., Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med, 2020. 2020: p. 6175964.
Mehta, P., et al., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020. 395(10229): p. 1033-1034.
Wilson, M.S. and T.A. Wynn, Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol, 2009. 2(2): p. 103-21.
Duong-Quy, S., et al., Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review. Pulm Ther, 2023. 9(3): p. 295-307.
Mylvaganam, R.J., et al., Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev, 2021. 30(162).
Solomon, J.J., et al., CT of Post-Acute Lung Complications of COVID-19. Radiology, 2021. 301(2): p. E383-e395.
Choudhary, R., et al., Effectiveness and Safety of Pirfenidone and Nintedanib for Pulmonary Fibrosis in COVID-19-Induced Severe Pneumonia: An Interventional Study. Cureus, 2022. 14(9): p. e29435.
Cojocaru, E., et al., Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment. J Pers Med, 2023. 14(1).
Mohammadi, A., et al., Post-COVID-19 Pulmonary Fibrosis. Cureus, 2022. 14(3): p. e22770.
Bharat, A., et al., Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med, 2021. 9(5): p. 487-497.
Patrucco, F., et al., Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks. Microorganisms, 2023. 11(4).
Montazersaheb, S., et al., COVID-19 infection: an overview on cytokine storm and related interventions. Virol J, 2022. 19(1): p. 92.
Kim, B.-G., et al., Risk of newly diagnosed interstitial lung disease after COVID-19 and impact of vaccination: a nationwide population-based cohort study. Frontiers in Public Health, 2024. 11.
Dhooria, S., et al., A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis, 2020. 37(2): p. 148-157.
Song, M.J., et al., Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Sci Rep, 2020. 10(1): p. 21218.
Al-Kuraishy, H.M., et al., Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology, 2022. 30(6): p. 2017-2026.
Humbert, M., et al., 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J, 2023. 61(1).
Copyright (c) 2024 Vonwicks C. Onyango
This work is licensed under a Creative Commons Attribution 4.0 International License.
